Cited 0 time in webofscience Cited 0 time in scopus

Dehydroevodiamine center dot HCl Protects Against Memory Impairment and Cerebral Amyloid-beta Production in Tg2576 Mice by Acting as a beta-Secretase Inhibitor

Title
Dehydroevodiamine center dot HCl Protects Against Memory Impairment and Cerebral Amyloid-beta Production in Tg2576 Mice by Acting as a beta-Secretase Inhibitor
Authors
Shin, KY[Shin, Ki Young]Noh, SJ[Noh, Su-Jin]Park, CH[Park, Cheol Hyoung]Jeong, YH[Jeong, Yun Ha]Chang, KA[Chang, Keun-A]Yoo, J[Yoo, Jakyung]Kim, HJ[Kim, Hee Jin]Ha, S[Ha, Sungji]Kim, HS[Kim, Hye-Sun]Park, HJ[Park, Hyun-Ju]Lee, JH[Lee, Jun-Ho]Moon, C[Moon, Cheil]Suh, YH[Suh, Yoo-Hun]
DGIST Authors
Moon, C[Moon, Cheil]
Issue Date
2016
Citation
CNS and Neurological Disorders: Drug Targets, 15(8), 935-944
Type
Article
Article Type
Article
Keywords
Alzheimer&aposs Disease (AD)Beta-SecretaseDehydroevodiamine?HclInhibitorMemory
ISSN
1871-5273
Abstract
We previously demonstrated that dehydroevodiamine•HCl (DHED), which was purified from Evodia rutaecarpa Bentham (Rutaceae), has beneficial effects on memory impairment and neuronal damage in three disease models. To investigate the preventive action of DHED in Alzheimer’s disease (AD), a progressive neurodegenerative disorder characterized by memory decline, amyloid-β (Aβ) protein-containing neuritic plaques and neurofibrillary tangles, in this study, we proposed that DHED may be therapeutically effective against the memory impairment and disease-related neurochemical changes that occur in Tg2576 (Tg) mice. DHED (0.5 mg/kg) was intraperitoneally administered to 7-month-old Tg and wild type mice for 4 months. In passive avoidance and water maze tests, DHED improved memory impairment of Tg mice after 4 months of administration. DHED also reduced cortical levels of soluble Aβ40, soluble Aβ42 and total Aβ peptides in the Tg mice. Additionally, we investigated whether DHED may be a β-secretase inhibitor that affects the production of Aβ related to the formation of neuritic plaques. DHED directly inhibited β-secretase activity in a concentrationdependent manner. The concentration required for 50 % enzyme inhibition (IC50) was 40.96 µM, and DHED may act as a competitive inhibitor of β-secretase. Moreover, DHED interacted strongly with BACE1 (β-secretase 2QP8), as demonstrated in the analysis of the binding mode of DHED in the active site of human BACE1. In conclusion, DHED may exhibit therapeutic effects for AD as a β-secretase inhibitor. © 2016 Bentham Science Publishers.
URI
http://hdl.handle.net/20.500.11750/2767
DOI
10.2174/1871527315666160815163723
Publisher
Bentham Science Publisher
Related Researcher
Files:
There are no files associated with this item.
Collection:
Brain and Cognitive SciencesETC1. Journal Articles


qrcode mendeley

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE